Press Releases - WDM Group PR Network
Apollo Hospitals Performs Complex Spinal Surgery on 10-Year-old
New Study Shows Marked Drop in PTSD Symptoms in Combat-Exposed Marines from Healing Touch and Guided Imagery
PENSRUS Pens October "Breast Cancer Awareness Month" With Sale on Pink Logoed Products
Contact information:
PENSRUS
www.pensrus.com
800-736-7787
Sirona Biochem to Present Scientific Poster at Canadian Diabetes Professional Conference
Julie Jang
Director, Communications
604.282.6065
jjang@sironabiochem.com
www.sironabiochem.com
Ablynx Reports Excellent Interim Results From Phase I/II Study With Its anti-IL-6R Nanobody, ALX-0061, in Rheumatoid Arthritis Patients
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX
M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com
Boston Therapeutics Wins FDA Approval to File an Abbreviated New Drug Application for PAZAMET(TM) to Treat Diabetes
Contact:
Boston Therapeutics, Inc.
Anthony Squeglia
Phone: 603-935-9799
Email: anthony.squeglia@bostonti.com
www.bostonti.com
Investor Relations:
MZ Group
Scott Powell
Senior Vice President
Phone: 212-301-7130
Email: scott.powell@mzgroup.us
Web: www.mz-ir.com
Threshold Pharmaceuticals Announces Presentation and Webcast at 11th Annual BIO Investor Forum
Contact
Laura Hansen, Ph.D.
Senior Director, Corporate Communications
Threshold Pharmaceuticals
Phone: 650-474-8206
E-mail: lhansen@thresholdpharm.com
Zenmark Names REVESTIVE (teduglutide): A New Drug for the Treatment of Short Bowel Syndrome
Contact:
Doug Powell
Office: 415-434-4800
Email: Email Contact
Sialix Executes Option Agreement; Appoints New Management Team to Advance Sialic Acid-Based Products for Treatment and Prevention of Cancer and Inflammation
Sialix contact:
Jeff Behrens
Chief Executive Officer
Sialix, Inc.
617 500-3455
Email Contact
Media contact:
Michelle Linn
Linnden Communications
O. 508 362 3087
M. 774 696 3803
Email Contact


